Triplet therapy showed promising efficacy in PD-L1–negative TNBC in the ATRACTIB trial, with a 63% response rate.
Triple-Negative Breast Cancer
Advertisement
Dr. Gradishar reviews PARP data, new combos, and tools to better select breast cancer patients for targeted treatment.
Dr. Mark Robson discusses PARP inhibitors in TNBC, including mechanisms, combos, biomarkers, and treatment sequencing.
Dr. Kelly McCann discusses evolving treatment sequencing strategies in metastatic triple-negative breast cancer.
Top research highlights from ESMO Breast Cancer 2025 showcase advances in treatment and care for patients with breast cancer.
Dr. David Waterhouse discusses geographic barriers to TNBC trials for Black women and the case for decentralized research.
TVEC plus chemo shows promise in early TNBC, boosting immune response and survival with favorable safety profile.
Emi-Le ADC shows promising activity in B7-H4–positive TNBC and endometrial cancer with a novel auristatin payload.
New ASCENT-04 data could shift first-line care in PD-L1+ TNBC. Dr. Rebecca Shatsky shares real-world insights from ASCO 2025.
Sacituzumab + pembrolizumab improved PFS vs chemo in PD-L1+ TNBC in ASCENT-04, with no new safety signals.
Sacituzumab + pembrolizumab improves PFS vs chemo in PD-L1+ TNBC, per ASCENT-04/KEYNOTE-D19 phase 3 trial at ASCO 2025.
Expert Interviews
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.